Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Techno DrugsDHA:TECHNODRUG -2.27%37 EV-to-FCF is -15.00 as of Jul. 24, 2026. GuruFocus rates DHA:TECHNODRUG with a GF Score™ of 37/100. The stock has 10 warning signs investors should review. Among 568 Drug Manufacturers companies, Techno Drugs ranks worse than 176056.16% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Techno Drugs's Enterprise Value is BDT9,023 Mil.
Techno Drugs's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was BDT-602 Mil. Therefore, Techno Drugs's EV-to-FCF for today is -15.00.
The historical rank and industry rank for Techno Drugs's EV-to-FCF or its related term are showing as below:
DHA:TECHNODRUG'
s EV-to-FCF Range Over the Past 10 Years
Min: -158.48 Med: -12.04 Max: -7.35
Current: -14.91
During the past 2 years, the highest EV-to-FCF of Techno Drugs was -7.35. The lowest was -158.48. And the median was -12.04.
DHA:TECHNODRUG's EV-to-FCF is ranked worse than 100% of 568
companies
in the Drug Manufacturers industry
Industry Median: 21.015
vs DHA:TECHNODRUG: -14.91
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Techno Drugs's PE Ratio (TTM) for today is calculated as:
Techno Drugs's share price for today is BDT47.30.
Techno Drugs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT1.530.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Techno Drugs EV-to-FCF Related Terms
Techno Drugs EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Techno Drugs's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:TECHNODRUG vs ZTS, UTHR, VTRS: EV-to-FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Techno Drugs's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Techno Drugs EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Techno Drugs's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Techno Drugs's EV-to-FCF falls into.
Techno Drugs's current Enterprise Value is BDT9,023 Mil.
Techno Drugs's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT-602 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Techno Drugs (DHA:TECHNODRUG) has a EV-to-FCF of -15.00 as of Jul. 24, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Techno Drugs and its competitors. According to the industry distribution chart, Techno Drugs ranks #999999 out of 568 companies in the Drug Manufacturers industry.
Is Techno Drugs' EV-to-FCF too high?
Techno Drugs' current EV-to-FCF is -15.00. Based on the distribution chart, Techno Drugs ranks #999999 out of 568 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Techno Drugs has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Techno Drugs' EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Techno Drugs ranks #999999 out of 568 companies for EV-to-FCF. This places Techno Drugs in the lower half of its industry. The industry median EV-to-FCF is 21.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.02, based on 568 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Techno Drugs and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Techno Drugs's current EV-to-FCF is -15.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Techno Drugs stock overvalued right now?
Techno Drugs (DHA:TECHNODRUG) has a current EV-to-FCF of -15.00. The current EV-to-FCF is -15.00. Techno Drugs' overall GF Score™ is 37/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Techno Drugs (DHA:TECHNODRUG), the current EV-to-FCF is -15.00 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Techno Drugs Ltd is a pharmaceutical company. The company manufactures medicines for the healthcare market with quality products, a distribution channel, and doctor-patient acceptance. The company is also engaged in production of Anti-Cancer medicines and medicines for therapeutic areas like oncology, cardiovascular, diabetes, immune suppressor, anesthetics, life-saving antibiotics & contrast media in Bangladesh. The product portfolio of the company include Algicar Plus, Amoclav Forte, Adesol Oral Solution, Aminovet Injection, Apegestrol Tab, Docetex 20 Inj, and others.
37GF Score
Get the complete analysis for DHA:TECHNODRUG
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:TECHNODRUG has been successfully added to your 
